← SynDRA
SILMITASERTIB
SynDRA canonical compound SYN0024154 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | CSNK2A2 |
|---|
| Mechanism of action | Casein kinase inhibitor |
|---|
All known targets
- CSNK2A1
- CSNK2A2
- DAPK3
- HIPK3
- CSNK2B
- PIM1
Mechanisms of action (all sources)
- Casein kinase inhibitor
- CSNK2A1 INHIBITOR
- Casein kinase II alpha inhibitor
- CSNK2A2 INHIBITOR
- DAPK3 INHIBITOR
- HIPK3 INHIBITOR
- PIM1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PGRMC1
- PDXK
- PDK1
- PDGFRB
- PDE4D
- PAK4
- PAK2
- PAICS
- OPA1
- OGG1
- NUAK2
- NTRK1
- NTHL1
- NQO2
- NLK
- NEK9
- PFKP
- PHKG2
- NEK3
- PIM2
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- NEK7
- NEK2
- PRKCD
- MAT2A
Cross-references
Synonyms
- CX-4945
- CX-4945 FREE ACID
- CX-4945 (SILMITASERTIB)
- CX4945
- SILMITASERTIB (CX-4945)
- CX 4945
- 5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid
- CX-4945 (Silmitasertib)
- UNII-C6RWP0N0L2
- 5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid
- 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid
- C6RWP0N0L2
- CHEMBL1230165
- AK-82006
- 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-Carboxylic Acid
- 5-((3-Chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic acid
- C19H12ClN3O2
- W-204393
- Cx-4945 free acid
- silmitasertibum
- RefChem:6223
- DTXCID9066093
- CX 4945 (Silmitasertib)
- Silmitasertib (CX-4945)
- Silmitasertib [INN]
- MFCD13184796
- CX4945 (Silmitasertib)
- 3NG
- Silmitasertib; CX 4945
- CX-4945 (Silmitaserib)
- SCHEMBL629082
- SILMITASERTIB [WHO-DD]
- GTPL8126
- orb1305875
- SCHEMBL29381056
- SCHEMBL30193004
- EX-A070
- CHEBI:232159
- CHEBI:232617
Look up SILMITASERTIB in the interactive SynDRA portal →